Post-split GSK to exit marquee world HQ, blueprinting smaller corporate digs
Days after GlaxoSmithKline unveiled plans for a major downsizing of its office footprint with plans to exit two iconic US sites, the pharma company shared that its world headquarters is getting the same treatment ahead of its consumer healthcare split.
Upon separating from GSK in mid-2022, the new consumer healthcare business is moving out of the landmark GSK House in Brentford, and investing nearly $164 million into its own, brand-new facility in Weybridge, the pharma said on Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,500+ biopharma pros reading Endpoints daily — and it's free.